High Potent API Manufacturing in India
HPAPI Manufacturers and Suppliers in India
Shilpa Pharma is one of India’s leading and most trusted High-Potent API (HPAPI) manufacturers, known for its advanced isolator technology and world-class containment capabilities. As the first company in India to establish a complete isolator-based HPAPI manufacturing system, we offer end-to-end solutions for the development and production of both oncology and non-oncology high-potent compounds.
Our high-containment facilities are engineered to safely handle OEL bands 1 to 5, enabling seamless support for projects ranging from small-scale development to large-scale commercial manufacturing. With nine dedicated cytotoxic manufacturing blocks and an independent analytical laboratory, Shilpa Pharma has built a strong global reputation for delivering high-quality, compliant, and reliable HPAPI solutions.
Whether you require early-stage development, scale-up, or full commercial production, Shilpa Pharma ensures precision, safety, and efficiency at every step—making us a preferred HPAPI partner for pharmaceutical companies worldwide.
Request a Quote for Pharma HPAPI Manufacturing and development Today
Fast Project Onboarding & Quick Tech Transfer
End-to-End HPAPI CDMO Support (OEL Band 1–5)
Dedicated High-Potency Cytotoxic Blocks
Our Expertise at a Glance
Leading the Way in Pharma Innovation
1987
Established
100+
R&D workforce
1500+
Team size
3
Manufacturing site
100+
Audits
500+
Customers
100+
Projects
Leading Highly Potent API Contract Manufacturing
Shilpa Pharma is recognised as one of the most trusted HPAPI CDMOs globally, offering end-to-end CDMO development support for high-potent molecules across oncology and specialty therapies. With India’s first and most advanced isolator-based high-containment CDMO infrastructure, we ensure absolute safety, precision, and purity throughout the development lifecycle—from preclinical to scale-up to commercial production. Our CDMO services are built around strict OEL Band 1–5 capabilities, allowing clients to confidently outsource even the most complex and sensitive HPAPI projects.
What makes Shilpa Pharma a preferred HPAPI CDMO partner worldwide is our ability to blend scientific depth, regulatory strength, and high-potency expertise under one roof. With nine dedicated cytotoxic CDMO blocks and a specialised analytical ecosystem, we consistently deliver reliable, compliant, and globally accepted HPAPI development outcomes. Companies choose us because we don’t just manufacture—we co-develop, optimise, and accelerate their high-potency pipeline with unmatched containment technology, operational excellence, and a proven record of supporting top global innovators.